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Pharmacodynamic Evaluation of the Intracellular Activity of
Antibiotics towards Pseudomonas aeruginosa PAO1 in a Model of
THP-1 Human Monocytes
Julien M. Buyck, Paul M. Tulkens, Françoise Van Bambeke
Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute; Université catholique de Louvain, Brussels, Belgium
Pseudomonas aeruginosa invades epithelial and phagocytic cells, which may play an important role in the persistence of infec-
tion. We have developed a 24-h model of THP-1 monocyte infection with P. aeruginosa PAO1 in which bacteria are seen multi-
plying in vacuoles by electronmicroscopy. The model has been used to quantitatively assess antibiotic activity against intracellu-
lar and extracellular bacteria by using a pharmacodynamic approach (concentration-dependent experiments over a wide range
of extracellular concentrations to calculate bacteriostatic concentrations [Cs] andmaximal relative efficacies [Emax]; Hill-Lang-
muir equation). Using 16 antipseudomonal antibiotics (three aminoglycosides, nine -lactams, three fluoroquinolones, and
colistin), dose-response curves were found to be undistinguishable for antibiotics of the same pharmacological class if data were
expressed as a function of the correspondingMICs. Extracellularly, all of the antibiotics reached a bacteriostatic effect at their
MIC, and their Emax exceeded the limit of detection (4.5 log10 CFU compared to the initial inoculum). Intracellularly, Cs values
remained unchanged for-lactams, fluoroquinolones, and colistin but were approximately 10 times higher for aminoglycosides,
whereas Emax values were markedly reduced (less negative), reaching3 log10 CFU for fluoroquinolones and only1 to1.5
log10 CFU for all other antibiotics. The decrease in intracellular aminoglycoside potency (higher Cs) can be ascribed to the acid
pH to which bacteria are exposed in vacuoles. The decrease in the Emax may reflect a reversible alteration of bacterial responsive-
ness to antibiotics in the intracellular milieu. The model may prove useful for comparison of antipseudomonal antibiotics to
reduce the risk of persistence or relapse of pseudomonal infections.
Pseudomonas aeruginosa is among the leading causes of noso-comial infections in humans, with a particular tropism for the
respiratory tract (see references 1 and 2 for reviews). Beside caus-
ing acute infections, it also chronically colonizes the lungs of cystic
fibrosis patients, causing protracted and relapsing infections that
are a primary cause of increased morbidity and mortality (3, 4).
P. aeruginosa is difficult to eradicate for at least two non-mutually
exclusive reasons. First,P. aeruginosa is not only naturally resistant to
many common antibiotics (because of the poor permeability of its
outer membrane) but can also express several mechanisms of resis-
tance to most, if not all, of the drugs that have been selected and
clinically developed over the years for their antipseudomonal activity
(2). Second, P. aeruginosa can adopt specificmodes of life that afford
protection from host defenses and antibiotic action. The first one
consistsof theproductionofbiofilm,aphysicalbarrier to theaccessof
antimicrobial agents that contributes to the persistence of infection
with P. aeruginosa (5). The second one stems from the capacity of P.
aeruginosa to invade and survive within eukaryotic cells. This has
been clearly documented for both epithelial (6–14) and phagocytic
(15) cells in vitro and also observed in vivo for lung epithelial cells and
alveolarmacrophages of infectedmice (16). Thus, although it is usu-
ally considered an extracellular organism, P. aeruginosamay actually
behave as anopportunistic intracellular organism.On thewhole, one
can estimate that approximately half of the clinical, laboratory, and
environmental isolates obtained demonstrate measurable internal-
ization (17). This ability to invade depends on multiple factors,
among which the level of expression of two secretion systems, H2
type VI and a type III secretion system,may play a critical role, as the
former favors and the latter inhibits internalization (8, 18).
Survival of bacteria in eukaryotic cells has been associated with
the reduced efficacy of most antibiotics, as demonstrated for
Staphylococcus aureus, Listeria monocytogenes, Legionella pneumo-
phila, andMycobacterium tuberculosis (see references 19 to 21 for
typical examples and references 22 and 23 for reviews). However,
no data are available regarding the activity of antipseudomonal
antibiotics against the intracellular forms of P. aeruginosa. The
aim of the present study was therefore to set up a model of intra-
cellular P. aeruginosa infection allowing a comparative evaluation
of the activities of antipseudomonal antibiotics. We selected
THP-1 human monocytes as host cells because these have proven
useful in obtaining reproducible levels of intracellular infection
with other bacteria and in quantitatively assessing the activities of
antibiotics by a pharmacodynamic approach (19, 20, 24–26). We
included in our studymost of the currently used antipseudomonal
agents (27) and tested them against reference strain PAO1.
MATERIALS AND METHODS
Bacterial strain, susceptibility testing, and time and dose-kill curve
studies in extracellular medium. P. aeruginosa strain ATCC PAO1 was
used for all experiments. Bacteria were grown in Mueller-Hinton broth,
and CFU counting was performed by plating on tryptic soy agar. MICs
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were measured by serial 2-fold microdilution according to CLSI guide-
lines (inoculum of approximately 106 CFU/ml, reading after 20 to 24 h of
incubation) in cation-adjustedMueller-Hinton broth (CA-MHB) (28) or
in the medium used for experiments with THP-1 cells (RPMI 1640 me-
dium supplemented with 10% fetal calf serum buffered at pH 7.4 with 10
mM phosphate buffer for MIC testing and with 2 g/liter NaHCO3 for cell
cultures incubated in a 5% CO2 atmosphere). Concentration-kill curves
were determined as previously described, with a starting inoculum of 106
CFU/ml (19) in the same media.
Cells, cell culture, and intracellular infection. Human THP-1 cells
were cultivated in RPMI 1640 medium supplemented with 10% fetal calf
serum as described previously (19). Intracellular infection was performed
on the basis of the protocol previously developed for S. aureus (19), with
specific adaptations. In brief, bacteria were opsonized by 1 h of incubation
with 10% human serum in RPMI 1640 medium without fetal calf serum.
Phagocytosis was allowed for 2 h at a bacterium/cell ratio of 10:1, after
which nonphagocytosed and adherent bacteria were eliminated by incu-
bation for 60 min with gentamicin at 100 mg/liter. After three washes in
phosphate-buffered saline (PBS) and resuspension in culture medium,
the inoculum was typically 5  105 to 7  105 CFU/mg of cell protein
(defined as time zero). Extracellular contamination at the end of the in-
cubation period was assessed in pilot experiments by CFU counting in
the culture fluid pooled with the liquids used for successive washings
(see Fig. 1).
Intracellular antibiotic activity. Antibiotics were added to infected
cells at extracellular concentrations ranging from 0.01 to 200 mg/liter to
obtain a complete description of the concentration-response curve, as
described in detail in a previous publication (19). After appropriate incu-
bation times (up to 24 h), cells were collected by centrifugation, resus-
pended in PBS, centrifuged again to eliminate extracellular bacteria, and
collected in distilled water. Complete cell lysis was achieved by sonication
(10 s), and lysates were used for determination of CFU counts (after plat-
ing on agar of appropriate dilutions) and of protein content by Lowry’s
assay with a commercially available detection kit (Bio-Rad DC Protein
Assay, Bio-Rad laboratories, Hercules, CA). The activity was expressed as
the change from the initial inoculum after 24 h of incubation.
Assessment of cell viability.The percentage of dead cells was assessed
by trypan blue exclusion test, with unstained and stained cells counted by
optical microscopy after 5 min of incubation with the dye at a final con-
centration of 0.5% in PBS.
Morphological studies. Infected cells were harvested, washed with
PBS, fixed with 2% glutaraldehyde (30 min, 4°C) in 0.1 M sodium caco-
dylate buffer (pH 7.4), washed, postfixed for 1 h with 1% osmium tetrox-
ide in cacodylate buffer in the dark, and then stained en bloc with uranyl
acetate (29). Ultrathin sections (75 nm) were counterstained with uranyl
acetate and lead citrate and observed in a Philips CM12 microscope.
Antibiotics.Amikacin (disulfate salt; potency, 73.6%), ticarcillin (dis-
ulfate salt; potency, 84.65%), piperacillin (sodium salt; potency, 94.2%),
and colistin (sulfate salt; potency, 67.50%) were purchased from Sigma-
Aldrich (St. Louis, MO). The following antibiotics were obtained as mi-
crobiological standards from their manufacturers: ciprofloxacin (chlo-
rhydrate; potency, 85%) and moxifloxacin (chlorhydrate; potency, 91%)
fromBayer AG,Wuppertal, Germany; tobramycin (potency, 100%) from
SMB-GalePhar, Marche-en-Famenne, Belgium; and imipenem (potency,
100%) fromMerck, Darmstadt, Germany. The following antibiotics were
procured as commercial products registered in Belgium or France for
parenteral use from their marketing authorization holders or resellers:
gentamicin (Gentalline; potency, 100%) fromMSD-France (Courbevoie,
France), levofloxacin (Tavanic; potency, 95%) from Aventis (Romain-
ville, France), piperacillin-tazobactam (Tazocin; potency, 97%) from
Wyeth Pharmaceuticals (Ottignies-Louvain-la-Neuve, Belgium),
cefepime (Maxipime; potency, 84.5%) and aztreonam (Azactam; po-
tency, 95.4%) from Bristol-Myers Squibb Co. (Brussels, Belgium), cefta-
zidime (Glazidim; potency, 88.2%) fromGlaxo-SmithKline (Genval, Bel-
gium), meropenem (Meronem; potency, 74.0%) from Astra Zeneca
(Brussels, Belgium), and doripenem (Doribax; potency, 95.7%) from
Janssen-Cilag (Beerse, Belgium).
Other reagents. Unless stated otherwise, all other reagents were of
analytical grade and were purchased from Sigma-Aldrich-Fluka. Cell cul-
ture or microbiology media were from Invitrogen (Paisley, Scotland) and
Difco (Sparks, MD).
Curve fittings and statistical analyses.Curve fittings were performed
with GraphPad Prism (version 4.02) software for Windows (GraphPad
Prism Software, San Diego, CA), and statistical analyses were performed
with GraphPad InStat 3 version 3.10 (GraphPad Prism Software).
RESULTS
Susceptibility testing. Table 1 shows the MICs of a series of anti-
biotics currently used for the treatment of infections with P.
aeruginosa, together with their maximal concentrations in serum
(Cmax) of humans (total drug) as determined in patients receiving
conventional dosages. MICs were measured in CA-MHB at pHs
7.4 and 5.5 to mimic the extracellular and phagolysosomal envi-
ronments, respectively, and in RPMI 1640 supplemented with
10% fetal calf serum (i.e., the medium used in experiments with
THP-1 cells). Acid pH decreased the potency of aminoglycosides
(MICs increased by at least 2 log2 dilutions) but not that of the
other antibiotics (maximum, 1-dilution increase). When mea-
sured in RPMI 1640, MICs were similar to or only 1 dilution
higher than those observed in CA-MHB.
Validation of the intracellularmodel. In a first series of exper-
iments, we examined in parallel (i) the level of internalization of
PAO1 by THP-1 cells exposed for 1 or 2 h to increasing inocula
and (ii) the extent of cell death induced by bacteria under these
conditions (Fig. 1, left panel). Internalization of bacteria clearly
increased with the inoculum and the time of incubation but was
accompanied by a commensurate toxicity for the host cells. On the
basis of these data, we selected a phagocytosis time of 2 h and an
initial bacterium-to-cell ratio of 10, which allowed us to obtain
reproducibly an intracellular inoculum of about 7 105 CFU/mg
cell protein with only 15% cell death. We then monitored, under
these conditions, the apparent intracellular growth of bacteria for
24 h in the presence of low concentrations of gentamicin. This
antibiotic was selected on the basis of the model developed previ-
ously for intracellular infection of THP-1 cells with S. aureus be-
cause it was shown to prevent extracellular contaminationwhile at
the same time only minimally impairing its intracellular growth
(19). As shown in Fig. 1 (right panel), the increase in the number
of cell-associated CFU at 24 h was almost as large as for bacteria
grown in CA-MHB as long as the gentamicin concentrations were
lower than the MIC measured in RPMI 1640. However, extracel-
lular contamination was very important (leading to an overesti-
mation of the cell-associated counts) and associated with a
marked (20%) loss of cell viability. When the extracellular gen-
tamicin concentration was brought to 5 mg/liter (i.e., close to its
MIC in RPMI 1640 [4 mg/liter]), extracellular contamination be-
came negligible but bacteria still grew in cells (with a gain of about
1 log10 CFU over the 24-h incubation period) and with no appar-
ent increase in cell toxicity (trypan blue assay). Any further increase
in the extracellular gentamicin concentration caused complete im-
pairmentof intracellular growth,denoting thedevelopmentof signif-
icant activity in cells beyond what was obtained against extracellular
bacteria.
Morphological studies. Electron microscopy was used to ex-
amine the morphology of infected cells, as well as the subcellular
localization of P. aeruginosa (Fig. 2). At the end of the phagocyto-
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sis period (2 h), we observed bacteria located in vacuoles limited
by a double membrane (suggesting a phagosomal nature) and
close to the cell surface, where they started multiplying. After 24 h
of incubation (in the presence of 5 mg/liter gentamicin in the
extracellular medium), we noticed the presence of larger vacuoles
hosting several bacteria.
Kinetics and influence of concentration on antibacterial ef-
fects in the MIC-to-Cmax range. The activity of antibiotics used
for the treatment of P. aeruginosa infections was first examined
over time and at fixed concentrations (1 theMIC in broth and at
the human Cmax) against both extracellular and intracellular bac-
teria with a panel of antibiotics covering the aminoglycoside, fluo-
roquinolone, and -lactam classes and colistin. These data are
illustrated for one representative antibiotic in each of these phar-
macological classes (gentamicin, ciprofloxacin, meropenem) and
for colistin in Fig. 3. With respect to extracellular activity, genta-
micin and colistin caused a transient decrease in the inoculum at 5
h when used at an extracellular concentration corresponding to
the MIC, and all antibiotics were eventually bacteriostatic at 24 h,
as anticipated. When used at its human Cmax (see Table 1 for
TABLE 1MICs of antibiotics in CA-MHB at pHs 7.4 and 5.5 and in RPMI 1640 against P. aeruginosa PAO1 compared to the Cmax
Antibiotic Abbreviation
MIC (mg/liter)
Dosagea
Human Cmax
(mg/liter)b Reference(s)
CA-MHB
RPMI 1640
(pH 7.4)pH 7.4 pH 5.5
Aminoglycosides
Gentamicin GEN 2 8 4 3–5 mg/kg/day i.v. 18 37
Amikacin AMK 4 64 4 7.5 mg/kg/day i.v. 38 37
Tobramycin TOB 1 8 1 3–5 mg/kg/day i.v. 6 37
-Lactams
Ticarcillin TIC 32 64 32 2 g/3–4 days i.v. 200 37
Piperacillin PIP 16 16 16 4 g/3–4 days i.v. 389 37
Piperacillin-tazobactam TZP 16 16 16 4 g/3–4 days i.v. 224 37
Cefepime CEP 4 8 4 2 g/2–3 days i.v. 160 37
Ceftazidime CAZ 2 4 2 2 g/2–3 days i.v. 160 37
Aztreonam ATM 8 16 8 2 g/3–4 days i.v. 210 37
Meropenem MEM 1 1 2 1 g/2–3 days i.v. 57 37, 38
Imipenem IMI 1 1 1 1 g/3–4 days i.v. 91 37, 38
Doripenem DOR 0.5 1 1 1 g/3–4 days i.v. 73 37, 38
Fluoroquinolones
Moxifloxacin MXF 1 2 1 0.4 g/day p.o.-i.v. 4.3 37
Levofloxacin LVX 1 2 1 0.5 g/day p.o.-i.v. 6.2 37
Ciprofloxacin CIP 0.125 0.25 0.125 0.4 g/day i.v. 4.6 37
Colistin (polymyxin) CST 1 2 2 2.5–5 mg/kg/day i.v. 5 39
a Conventional doses for the treatment of P. aeruginosa infections. p.o., oral; i.v., intravenous.
b Cmax, commonly observed maximal concentration (total drug) in serum after intravenous or oral administration of these doses.
FIG 1 Setting up the intracellular model. (Left panel) Internalization of P. aeruginosa PAO1 after 1 (gray bars) or 2 (open bars with black border) h of
phagocytosis of PAO1 at increasing bacterium-to-cell ratios (left axis) and percentmortality of THP-1 cells as assessed at the end of the phagocytosis period (right
axis). All data aremeans standard deviations (n 3). (Right panel) Apparent intracellular growth ofP. aeruginosaPAO1 in THP-1 cells incubated for 24 hwith
increasing extracellular concentrations of gentamicin compared to the extracellular growth (dotted gray line)measured in RPMI culturemedium supplemented
with 10% fetal calf serum in the absence of antibiotic. The graph shows the change in the number ofCFU (logCFU), from the initial, postphagocytosis inoculum
achieved after 2 h of phagocytosis for an initial inoculum of 10 CFU/cell (approximately 7  105 CFU/mg of protein). The table shows the percentages of
contamination of the culturemediumby P. aeruginosa and of cell death at the end of the experiment. GEN, gentamicin. All data aremeans standard deviations
(n 3).
Buyck et al.
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values), gentamicin was rapidly bactericidal toward extracellular
bacteria, yielding a decrease in the CFU count corresponding to
the limit of detection at 5 h. Ciprofloxacin and meropenem were
also bactericidal against extracellular bacteria at 5 h (3 log10 CFU
decrease), but colistin required 24 h of incubation to reach this
threshold. With respect to intracellular activity, gentamicin and
colistin did not prevent bacterial growth when used at extracellu-
lar concentrations corresponding to their MICs, while mero-
penem and ciprofloxacin reached a bacteriostatic effect after 24 h
of incubation. At the humanCmax, colistin still did not completely
impair the intracellular growth of P. aeruginosa, gentamicin was
bacteriostatic, andmeropenem and ciprofloxacin caused 1.5- and
3-log10 CFU decreases at 24 h, respectively. Full data for the other
antibiotics tested (amikacin, tobramycin, moxifloxacin, levo-
floxacin, piperacillin, piperacillin-tazobactam, ticarcillin, ceftazi-
dime, cefepime, imipenem, doripenem, and aztreonam) are
shown in Fig. S1 in the supplemental material together with those
of the four antibiotics described above. Globally, all of the antibi-
otics were bacteriostatic at their MICs at 24 h against extracellular
bacteria and bactericidal at their Cmax, with the exception of
cefepime. Together with gentamicin, amikacin was the only anti-
biotic capable of sterilizing the culture in 5 h. Against intracellular
bacteria and at 24 h, aminoglycosides did not prevent intracellular
growth when added to the culture medium at concentrations cor-
responding to their MICs in RPMI 1640 medium, whereas all
-lactams were bacteriostatic and fluoroquinolones showed vari-
able effects. At extracellular concentrations corresponding to their
Cmax, aminoglycosides were almost bacteriostatic at 24 h, -lac-
tams reduced the inoculum by approximately 1 log10 CFU, but
fluoroquinolones reduced the intracellular inoculum by close or
equal to 3 log10 CFU compared to the postphagocytosis value.
Concentration-effect relationships (pharmacological com-
parisons). Because only minimal decreases in intracellular CFU
counts were observed at 5 h, full pharmacological concentration-
response studies (aimed at determining and comparing the appar-
ent bacteriostatic concentrations [Cs] andmaximal relative effica-
cies [Emax] of antibiotics against extracellular and intracellular
bacteria) weremade only after 24 h of incubation. Typical data are
illustrated in Fig. 4 for the same four representative antibiotics. In
all cases, monophasic sigmoidal functions (with a slope factor of
1) could be fitted to the experimental values and these were used
for interpretation of the data. Against extracellular bacteria, an
apparent bacteriostatic effect was observed for each antibiotic at
concentrations close to theMIC and theEmaxwas always below the
actual limit of detection (4.5-log10 decrease compared to the orig-
inal inoculum). Emax values were considerably lower (less nega-
tive) against intracellular bacteria than against extracellular bac-
teria for all four drugs, reaching only a 1- to 1.5-log10 CFU
decrease from the original, postphagocytosis inoculum for colis-
tin, gentamicin, andmeropenem and a 2.6-log10 CFUdecrease for
ciprofloxacin. The Cs of colistin, meropenem, and ciprofloxacin
were close to the MICs (measured at pH 7.4), while that of genta-
micin was about 10-fold higher. These studies were then extended
to 12 other antibiotics, and the corresponding data (grouped by
drugs of the same pharmacological class) are illustrated in Fig. 5
(for matching pharmacodynamic parameters for each individual
antibiotic, see Table S1 in the supplemental material). Quite in-
terestingly, all of the antibiotics within a pharmacological class
showed similar activity profiles when the extracellular concentra-
tions were expressed in multiples of the respective MICs (at pH
7.4). A single curve could thus be fitted to the whole set of data
obtained with different antibiotics within that class (Table 2 con-
tains the pharmacodynamic parameters calculated from these sin-
gle-fit curves; see Tables S1 to S3 in supplemental material for the
pharmacodynamic parameters of individual curves and detailed
statistical analyses); only the aztreonam and amikacin intracellu-
lar Emax values were significantly different from those of their re-
spective classes, and only the tobramycin EC50 (concentration
yielding a response halfway between the Emin and Emax responses
in concentration-dependent experiments) was significantly dif-
ferent from that of the other aminoglycosides. Two major obser-
vations could bemade from these studies. First, theCs values were
similar for intracellular and extracellular bacteria with -lactams
and fluoroquinolones but were globally 10 times higher (lower
potency) for aminoglycosides. Second, the Emax values for intra-
cellular P. aeruginosawere lower (less negative) than those of their
extracellular counterparts but to a variable extent. Thus, the Emax
still reached about2.9 log10 CFU for fluoroquinolones but only
about1.2 log10 CFU for all other antibiotics. The MICs for bac-
teria collected at the end of the experiment were measured and
found to be unchanged from those for the infecting strain, indi-
cating that we were not dealing with the mere selection of stable
resistant subpopulations (data not shown).
DISCUSSION
The present study has allowed the development of a well-defined
24-h model of intracellular infection of phagocytic cells with P.
aeruginosa that could be used to document the response of intra-
cellular P. aeruginosa to antibiotics on a pharmacodynamic basis.
Considering the model, optimization of the bacterium-to-cell
ratio and the time of phagocytosis was critical in obtaining a re-
FIG 2 Electron microscopic appearance of THP-1 cells infected with P.
aeruginosa PAO1. Infected cells were observed after 2 h of phagocytosis (cor-
responding to the postphagocytosis conditions) and after 24 h of incubation in
the presence of gentamicin at an extracellular concentration of 5mg/liter. Bars,
1 m.
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producible infection while at the same time avoiding extensive
killing of the host cells. This is important for P. aeruginosa because
it produces a variety of virulence factors that can affect host cell
viability. In strain PAO1, pili, flagella, a type III secretion system,
exotoxin A, and lipopolysaccharide are all known to contribute to
virulence (30, 31). Because the expression of these factors is vari-
able between strains and critically depends on their growth status,
preliminary investigations such as those performed here will
probably be necessary when expanding the model to other labo-
ratory or clinical strains. Selection of the appropriate extracellular
concentration of gentamicin to prevent extracellular contamina-
tion without impairing the intracellular growth of P. aeruginosa
also proved to be critical. Our data suggest that a concentration
close to the MIC for the strain (as determined in cell culture me-
dium at pH 7.4) is the most appropriate, as previously established
in a model of S. aureus-infected THP-1 cells (19), but we also see
that both lower and higher concentrations may give rise to spuri-
ous results. Lastly, we show that P. aeruginosa is able to grow
slowlywithin THP-1monocytes, with a net population increase of
about 1 log10 CFU over 24 h. However, it must be emphasized that
intracellular growth seems to start only after a 5-h period follow-
ing phagocytosis. In this context, few studies have monitored the
long-term intracellular fate of P. aeruginosa, which makes com-
parisons of other models with ours quite difficult. However, pro-
longed intracellular persistence of P. aeruginosa has been demon-
strated in airway epithelial cells (14) or in HeLa cervical cancer
cells (8) and transient growth has been demonstrated in corneal
epithelial cells (9). A switch from apparent intracellular persis-
tence to a net increase in the number of intracellular bacteria is
probably related to an equilibrium among intrinsic bacterial
growth properties, expression of virulence factors, and the level of
host defenses. The latter are notoriously poor in THP-1 cells (32).
Electron microscopy suggests that intracellular P. aeruginosa re-
mains confined in vacuoles in THP-1 cells for at least 24 h and can
actively replicate therein. A vacuolar localization of P. aeruginosa
has also been generally observed in epithelial cells (7, 13, 33), but
the nature of the infected vacuoles has not yet been determined
(31).
Moving now to the use of themodel for the study of antibiotics,
we show here that their general pharmacodynamic profile is glob-
ally comparable to that observed in the same host cells for other
bacteria such as S. aureus, L. monocytogenes, and L. pneumophila
(19, 20, 24–26). Thus, (i) all antibiotics clearly showed concentra-
tion-dependent effects following the general model described for
drugs in interaction with their targets and described by the Hill-
Langmuir sigmoid function, (ii) the relative intracellular Emax is
FIG 3 Influence of time on the rate and extent of activity of antibiotics against extracellular (broth; left panels) and intracellular (THP-1cells; right panels) P.
aeruginosa PAO1 upon incubation at fixed extracellular concentrations corresponding to their MICs in broth (top) and to concentrations (total drug) corre-
sponding to their Cmax observed in humans after the administration of conventional doses (bottom). The ordinate shows the change in the number of CFU (log
scale) per milliliter for extracellular bacteria or per milligram of cell protein for intracellular bacteria. The solid horizontal line corresponds to a bacteriostatic
effect (no change from the initial inoculum), and the dotted horizontal line shows the limit of detection (4.5-log CFU decrease). Values are means standard
deviations (n 3); when not visible, error bars are smaller than the symbols. GEN, gentamicin; MEM, meropenem; CIP, ciprofloxacin; CST, colistin.
Buyck et al.
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always considerably lower than that observed in broth, and (iii)
the apparent Cs for intracellular bacteria is similar to the value for
bacteria in broth, except that of aminoglycosides (which is mark-
edly increased, denoting a corresponding loss of potency). Re-
markably, all of the drugs within a given pharmacological class
behave similarly when the bacterial response is expressed as a
function ofmultiples of the respectiveMICs. This suggests that the
intracellular activity of antibiotics depends on the intrinsic activity
shown in broth (MIC), which will determine the Cs on the one
hand, and on their pharmacological class, which will determine
their relative Emax on the other hand. The latter parameter reflects
the maximal killing capacity of a given antibiotic in a specific en-
vironment. It therefore takes into account not only the way the
drug can express its activity in the infected compartment but also
the bacterial responsiveness to that antibiotic and the cooperation
with cell defense mechanisms to achieve killing (22). The marked
reduction in maximal relative intracellular efficacy (compared to
what is seen in broth) must therefore be interpreted as clear evi-
dence that a significant part of the intracellular inoculum appar-
ently becomes insensitive to the action of the antibiotic. This
could be explained by the slow growth of bacteria when in the
intracellular milieu or the ability of intracellular P. aeruginosa to
switch to a less susceptible phenotype.While slow growthhas been
documented here, we know that P. aeruginosa may adopt a bio-
film-like phenotype inside cells that makes it poorly responsive to
antibiotics (14). Both changes, however, must be reversible be-
cause no difference in the MIC was noticed when testing bacteria
collected from cells (after phagocytosis and exposure of these cells
to antibiotics for 24 h) in comparison with bacteria maintained in
broth.
Our previous studies using the THP-1 monocyte model allow
comparison of the pharmacodynamic properties of antibiotics
against bacteria located in distinct subcellular compartments of
the same host. Against an organism that thrives in vacuoles, such
as S. aureus, the Emax values of aminoglycosides and -lactams are
of the same order of magnitude as those seen here (about 1 to
1.5 log10 CFU). The values of fluoroquinolones seem species
specific, varying from 2 log10 CFU for S. aureus (25, 34, 35) to
2 to3 log10CFU forL. pneumophila (25) and3 log10CFU for
P. aeruginosa. Against an organism multiplying in the cytosol,
such as L. monocytogenes, the Emax values of both -lactams (2
log10 CFU) and fluoroquinolones (3 to 4 log10 CFU) are
higher (more negative) (24–26) than those we observed here and
aminoglycosides are totally ineffective (36). Available data (re-
viewed in references 22 and 23) show that -lactams and fluoro-
quinolones, although they are recovered mainly in the cytosol
after cell fractionation studies, are probably capable of moving
freely throughout all cell compartments. Conversely, aminoglyco-
sides are always found associated with, and probably restricted to,
the endocytic and lysosomal compartment of the cells. Thus, while
FIG 4 Concentration-response curves of selected antibiotics against extracellular and intracellular P. aeruginosa. The graphs show the changes in the number of
CFU (log CFU from the initial inoculum) permilliliter of broth (extracellular, open symbols, dotted lines) or permilligram of cell protein (intracellular, closed
symbols, solid lines) in THP-1 cells after 24 h of incubation at increasing extracellular concentrations (expressed in milligrams per liter [total drug]). The solid
horizontal line corresponds to a bacteriostatic effect (no change from the initial inoculum); the vertical dotted lines show theMIC-to-Cmax range limits. Data are
means standard deviations (n 3); when not visible, error bars are smaller than the symbols.
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-lactams, fluoroquinolones, and aminoglycosides can be effec-
tive against intravacuolar P. aeruginosa and S. aureus if their ex-
tracellular concentration is high enough (which is what the Emax
will document), only -lactams and fluoroquinolones might be
able to reach and act on cytosolic L. monocytogenes. Access to
target only, however, does not explain why fluoroquinolones are
more effective against intracellular P. aeruginosa than against in-
tracellular S. aureus (when comparing these two bacteria in the
same cell host) and more effective than -lactams against P.
aeruginosa in the model studied here. This suggests a specific role
of bacterial responsiveness to fluoroquinolones that needs to be
investigated further.
Previous studies with other bacteria showed that the relative
potencies of drugs rely on their MICs on the one hand (intrinsic
potency) and on their cellular concentrations on the other (for a
review, see reference 23). We have selected the Cs as a more useful
parameter than the EC50 commonly used to describe relative an-
tibiotic potencies in pharmacological studies. This is because EC50
are critically dependent on the amplitude of the concentration-
response curve, which in our case is entirely related to the Emax
(the Emin, which describes bacterial growth in the absence of an
antibiotic, is essentially similar for all of the groups studied here).
Thus, a given EC50 may actually correspond to very different bac-
terial response levels (growth, an apparent bacteriostatic effect, or
a decrease in the CFU count), depending on howmuch lower the
Emax value is than that of the initial inoculum, which makes it
poorly informative in terms of an antibacterial effect. Conversely,
the Cs for intracellular bacteria tends to be constant when com-
paring antibiotics (even if the Emax values are different) and actu-
ally close to theMICmeasured in broth or in RPMI 1640medium
for all antibiotics except aminoglycosides. While -lactams reach
intracellular concentrations close to the extracellular ones, fluo-
roquinolones accumulate to much higher concentrations in cells
(22). Themost plausible explanation for the fact that fluoroquino-
lones are not more potent than -lactams against intracellular
bacteria is that only a fraction of an accumulated fluoroquinolone
FIG 5 Concentration-response curves of antibiotics against extracellular and intracellular P. aeruginosa. The graphs show changes in the number of CFU (log
CFU from the initial inoculum) permilliliter of broth (extracellular; open symbols and dotted line) or permilligram of cell protein (intracellular; closed symbols
and solid line) in THP-1 cells after 24 h of incubation at increasing extracellular concentrations (expressed in multiples of the MIC). The solid horizontal line
corresponds to a bacteriostatic effect (no change from the initial inoculum); the vertical dotted line shows theMIC. Data are means standard deviations (n
3); when not visible, error bars are smaller than the symbols. For definitions of drug name abbreviations, see Table 1.
TABLE 2 Pertinent regression parameters of dose-response curves for extracellular (broth) and intracellular (THP-1 cells) activities of antibiotics
against strain PAO1a
Antibiotic(s)
Mean extracellular activity (95% confidence interval) Mean intracellular activity (95% confidence interval)
Emin
b Emax
c EC50
d Cs
e R2 Emin
b Emax
c EC50
d Cs
e R2
Aminoglycosides 3.80 (3.37–4.23)aAf 4.5A 1.77 (1.31–2.37)aA 1.18 0.90 3.34 (3.04–3.64)aA 1.31 (1.62 to1.00)aB 4.22 (3.01–5.93)aA 10.77 0.83
-Lactams 3.77 (3.57–3.98)aA 4.5A 1.58 (1.37–1.83)aA 1.17 0.93 2.74 (2.60–2.88)bB 1.23 (1.34 to1.11)aB 0.44 (0.36–0.53)bA 0.98 0.90
Fluoroquinolones 4.10 (3.57–4.63)aA 4.5A 1.61 (1.29–2.00)aA 1.21 0.94 3.02 (2.65–3.39)aB 2.88 (3.13 to2.63)bB 1.00 (0.73–1.36)bA 1.04 0.91
Colistin 3.81 (2.75–4.87)aA 4.5A 1.78 (1.08–2.95)aA 1.25 0.92 2.84 (2.50–3.18)bB 1.04 (1.22 to0.86)aB 0.94 (0.63–1.40)bA 2.52 0.92
a Cells were incubated for 24 h with extracellular drug concentrations ranging from 0.01 to 200 mg/liter. A single curve was fitted to the data obtained for different
antipseudomonal antibiotics within a single class. The corresponding data are shown in Fig. 5; for the parameters for the individual fits, see Table S1 in the supplemental material.
b CFU count increase (in log10 units) at 24 h from the corresponding initial inoculum as extrapolated for an infinitely low antibiotic concentration.
c CFU count decrease (in log10 units) at 24 h from the corresponding initial inoculum as extrapolated from an infinitely high antibiotic concentration.
d Extracellular concentration (total drug; in multiples of the MIC) causing a reduction halfway between Emin and Emax, as calculated from the Hill equation of the concentration-
response curve (slope factor of 1).
e Cs, i.e., the extracellular concentration (total drug; in multiples of the MIC) resulting in no apparent bacterial growth (number of CFU identical to the initial inoculum), as
calculated from the Hill equation of the concentration-response curve.
f Statistical analysis per column was done by one-way analysis of variance with Tukey’s test for multiple comparisons of each parameter for all classes. Values followed by different
lowercase letters are significantly different from each other (P	 0.05). Statistical analysis per row was done by unpaired, two-tailed t test between corresponding parameters of
extracellular and intracellular activities. Values followed by different uppercase letters are significantly different from each other (P	 0.05).
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expresses its activity at the site of action, as already concluded
from studies assessing the susceptibility of intracellular S. aureus
and L. monocytogenes to fluoroquinolones with distinct levels of
accumulation (see reference 26 and the references cited therein).
Colistin accumulation and subcellular distribution are still un-
known, making any discussion premature in this context. For
aminoglycosides, themarked difference inCs for intracellular bac-
teria from the MIC measured in broth at neutral pH can be un-
derstood if considering that both the drug and the target could be
located in an acidic environment (lysosomes and phagolysosomes
on the basis of the data from our electron microscopic studies).
The Cs of aminoglycosides for intracellular bacteria are actually
close to their MICs if measured at pH 5.5. Data in the literature,
however, suggest that the vacuoles in which P. aeruginosa survives
and multiplies may be distinct from lysosomes (and therefore not
as acidic), at least in epithelial cells (33). Further studies aimed at
identifying the real nature of the vacuoles identified here and at
determining their actual pH would be useful in this context.
The present study used only one reference strain of P. aerugi-
nosa (ATCC PAO1), which may be considered a major limitation
to the application of our conclusions to clinical situations. The
choice of a unique, well-characterized strain was actually essential
for the development and validation of themodel, as well as for the
correct comparative assessment of the intrinsic intracellular activ-
ity of each antibiotic class. Many resistance mechanisms and vir-
ulence factors vary in their level of expression in clinical strains,
depending on the environment. This would have created much
uncertainty in what is primarily a pharmacological study. Focus-
ing on this aspect, our data show a clear superiority of fluoro-
quinolones over -lactams and aminoglycosides when dealing
with intracellular forms of P. aeruginosa. They also highlight the
poor efficacy of colistin against these forms. Within the limita-
tions inherent to all in vitro experiments, including those that are
specific to the model used and that are discussed in details in our
previous publications (19, 20, 24), our studies may represent a
first step in the rationalization of current antibiotic choices and in
the better assessment of new molecules. Further studies examin-
ing key clinical strains and other host cells but based on a similar
pharmacodynamic approachmay eventually further contribute to
limitation of the risk of therapeutic failures related to persistence
and/or recurrence of pseudomonal infections.
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Table S1. Pertinent regression parameters of dose-response curves for intracellular and extracellular activity of antibiotics against 
PAO1 strain a. 
 
Extracellular activityc  Intracellular activity a Antibiotic 
Emind Emaxd EC50e Csf R²  Emind Emaxd EC50e Csf R² 
GEN 3.66 (3.20 to  4.11) 
>-4.5 
 
0.63 
(0.47 to 0.84) 0.46 0.98  
2.76 
(2.44 to 3.08 
-1.59 
(-1.96 to -1.23) 
3.30 
(2.18 to 4.99) 5.70 0.96 
AMK 3.70 (3.01 to 4.39) 
>-4.5 
 
1.20 
(0.79 to 1.82) 0.69 0.94  
3.78 
(3.33 to 4.22) 
-2.17 
(-2.79 to -1.55) 
2.04 
(1.32 to 3.14) 3.53 0.89 
TOB 4.28 (2.76 to 5.81) >-4.5 
0.69 
(0.42 to 1.14) 0.55 0.90  
2.99 
(2.63 to 3.36) 
-1.02 
(-1.38 to -0.65) 
3.64 
(2.26 to 5.86) 10.69 0.88 
Aminoglycosidesg 3.83 (3. 37 to 4.28) >-4.5 
0.74 
(0.57 to 0.98) 0.56 0.93  
3.34 
(3.04 to 3.64) 
-1.31 
(-1.62 to -1.00) 
2.12 
(1.51 to 2.98) 5.40 0.84 
MXF 4.04 (3.21 to 4.87) >-4.5 
1.97 
(1.40 to 2.77) 
1.28 
 0.94  
2.75 
(2.49 to 3.01) 
-2.87 
(-3.11 to -2.64) 
1.10 
(0.85 to 1.42) 1.05 0.98 
LVX 3.94 (3.00 to 4.88) 
>-4.5 
 
1.82 
(1.11 to 2.98) 1.37 0.90  
3.45 
(2.86 to 4.04) 
-3.22 
(-3.58 to -2.88) 
0.49 
(0.30 to 0.79) 0.48 0.95 
CIP 4.66 (3.49 to 5.82) >-4.5 
1.09 
(0.74 to 1.60) 0.98 0.93  
3.15 
(2.39 to 3.90) 
-2.66 
(-3.02 to -2.29) 
2.15 
(1.22 to 3.77) 2.55 0.92 
Fluoroquinolonesg 4.10 (3.57 to 4.63) >-4.5 
1.61 
(1.29 to 2.00) 1.21 0.94  
3.02 
(2.65 to 3.39) 
-2.88 
(-3.13 to -2.63) 
1.00 
(0.73 to 1.36) 1.04 0.91 
TIC 3.24 (3.01 to 3.47) >-4.5 
0.54 
(0.33 to 0.75) 1.27 0.97  
2.53 
(2.33 to 2.73) 
-1.44 
(-1.71 to -1.17) 
0.59 
(0.43 to 0.82) 1.04 0.96 
PIP 3.87 (3.46 to 4.27) >-4.5 
1.94 
(1.37 to 2.76) 1.29 0.97  
2.96 
(2.64 to 3.28) 
-1.13 
(-1.41 to -0.85) 
0.26 
(0.17 to 0.40) 0.68 0.96 
TZP 3.69 (3.22 to 4.15) >-4.5 
1.85 
(1.22 to 2.86) 1.36 0.94  
2.50 
(2.27 to 2.74) 
-0.91 
(-1.22 to -0.61) 
0.56 
(0.33 to 0.95) 1.54 0.95 
FEP 3.97 (3.15 to 4.79) >-4.5 
1.29 
(0.81 to 2.04) 0.93 0.92  
3.14 
(2.62 to 3.66) 
-1.52 
(-1.93 to -1.11) 
0.75 
(0.42 to 1.34) 1.56 0.93 
CAZ 3.51 (3.01 to 4.00) >-4.5 
1.97 
(1.40 to 2.78) 1.45 0.96  
3.13 
(2.56 to 3.69) 
-1.33 
(-1.67 to -1.00) 
0.31 
(0.19 to 0.53) 0.74 0.85 
ATM 3.87 (3.43 to 4.31) 
-4.36 
(-5.02 to -3.69) 
1.67 
(1.18 to 2.36) 1.48 0.92  
2.92 
(2.62 to 3.22) 
-0.75 
(-0.99 to -0.52) 
0.20 
(0.14 to 0.30) 0.79 0.96 
MER 4.62 (3.17 to 6.06) >-4.5 
1.02 
(0.55 to 1.89) 0.74 0.92  
2.65 
(2.17 to 3.13) 
-1.57 
(-1.80 to -1.34) 
0.36 
(0.23 to 0.57) 0.61 0.94 
IMI 4.23 (3.62 to 4.85) >-4.5 
0.77 
(0.47 to 1.25) 0.63 0.97  
2.80 
(2.42 to 3.19) 
-1.07 
(-1.33 to -0.81) 
0.74 
(0.47 to 1.17) 1.95 0.92 
DOR 3.51 (2.77 to 4.26) >-4.5 
1.98 
(1.34 to 2.94) 1.51 0.93  
2.11 
(1.72 to 2.51) 
-1.33 
(-1.60 to -1.08) 
1.21 
(0.74 to 1.98) 1.91 0.95 
β-lactamsg 3.77 (3.57 to 3.98) >-4.5 
1.58 
(1.37 to 1.83) 1.16 0.93  
2.74 
(2.60 to 2.88) 
-1.23 
(-1.34 to -1.11) 
0.44 
(0.36 to 0.53) 0.98 0.90 
CST 3.81 (2.75 to 4.87) > -4.5 
1.78 
(1.08 to 2.95) 1.25 0.92  
2.84 
(2.50 to 3.18) 
-1.04 
(-1.22 to -0.86) 
0.94 
(0.63 to 1.40) 2.52 0.92 
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a Data are based on a 24-h post-phagocytosis exposure. Regression parameters were calculated using all data from antibiotic concentrations of 10−2 to 103 to times the MIC. The 
parameters described in the table were derived from analysis of the curve shown in Fig 5. See Table S2 and 3 for statistical analyses 
b Determined in THP-1 macrophages with an initial phagocytosed inoculum of about 106 CFU/mg of protein. 
d Log CFU decrease at 24 h from the corresponding original inoculum, as extrapolated for an infinitely large antibiotic concentration. Samples yielding less than −5 log CFU were 
considered below the detection level. 
e extracellular concentrations (total drug; in multiples of the MIC) causing a reduction of the inoculum halfway between the initial (E0) and the maximal (Emax) values, as obtained from the 
Hill equation. 
f Static concentration, i.e., the extracellular concentration (total drug; in multiples of the MIC) resulting in no apparent bacterial growth (number of CFU identical to the initial inoculum), as 
calculated from the Hill equation of the concentration-response curve. 
g reproduced from Table 2; data from all antibiotics within the class were used to fit a single curve  
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Table S2: statistical analyses of EC50 presented in Table S1 
Black and dark gray cells compare parameters for extracellular and intracellular activity of individual antibiotics (black) or classes as a whole 
(dark grey) (***; p< 0.01; NS, not significant). 
Colored cells compare antibiotics within a same class (orange: aminoglycosides; green: β-lactams; blue: fluoroquinolones) or classes as whole 
among them (yellow). Light and dark colors correspond to statistical analysis for extracellular and intracellular activities, respectively (*: p<0.05; 
NS: not significant). 
 
Antibiotics EC50 
AMIN. GEN AMK TOB Blact TIC PIP TZP FEP CAZ ATM MEM IMI DOR FQ LVX MOX CIP CST 
AMIN. *** NS NS * *          *    * 
GEN NS *** NS NS                
AMK NS * NS NS                
TOB NS NS * ***                
Blact NS    NS NS NS NS NS NS NS NS  NS NS NS    NS 
TIC     NS NS NS NS NS NS NS NS NS NS      
PIP     NS NS NS NS NS NS NS NS  NS NS      
TZP     NS NS NS NS NS NS NS NS NS NS      
FEP     NS NS NS NS NS NS NS NS NS NS      
CAZ     NS NS NS NS NS NS NS NS NS NS      
ATM     NS NS NS NS NS NS NS NS NS NS      
MEM     NS NS NS NS NS NS NS NS NS NS      
IMI     NS NS NS NS NS  NS NS NS NS NS      
DOR     NS NS NS NS NS NS NS NS NS NS      
FQ NS    NS          NS NS NS NS NS 
LVX               NS NS NS NS  
MOX               NS NS NS NS  
CIP               NS NS NS NS  
A
n
t
i
b
i
o
t
i
c
s
 
CST NS    NS          NS    NS 
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Table S3: statistical analyses of Emax presented in Table S1 
Black and dark gray cells compare parameters for extracellular and intracellular activity of individual antibiotics (black) or classes as a whole 
(dark grey) (***; p< 0.01; NS, not significant). 
Colored cells compare antibiotics within a same class (orange: aminoglycosides; green: β-lactams; blue: fluoroquinolones) or classes as whole 
among them (yellow). Light and dark colors correspond to statistical analysis for extracellular and intracellular activities, respectively (*: p<0.05; 
NS: not significant; NA: not applicable [because Emax > detection limit]). 
 
Antibiotics Emax 
AMIN. GEN AMK TOB Blact TIC PIP TZP FEP CAZ ATM MEM IMI DOR FQ LVX MOX CIP CST 
AMIN. *** NS * NS NS          *    NS 
GEN NA *** NS *                
AMK NA NA *** NS                
TOB NA NA NA ***                
Blact NA    *** NS NS NS NS NS * NS  NS NS *    NS 
TIC     NA *** NS * NS NS * NS NS NS      
PIP     NA NA *** NS NS NS NS * NS NS      
TZP     NA NA NA *** * * NS * NS *      
FEP     NA NA NA NA *** NS * NS * NS      
CAZ     NA NA NA NA NA *** * NS NS NS      
ATM     NA NA NA NA NA NA *** * NS *      
MEM     NA NA NA NA NA NA NA *** NS NS      
IMI     NA NA NA NA NA NA NA NA *** NS      
DOR     NA NA NA NA NA NA NA NA NA ***      
FQ NA    NA          *** NS NS NS * 
LVX               NA *** NS *  
MOX               NA NA *** NS  
CIP               NA NA NA ***  
A
n
t
i
b
i
o
t
i
c
s
 
CST NA    NA          NA    *** 
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Figure S1. Influence of the time on the rate and extent of activity of antibiotics against 
extracellular and intracellular P. aeruginosa PAO1 upon incubation at a fixed extracellular 
concentration corresponding to their MIC in broth (open symbols and dotted lines) and to 
their maximal concentration (total drug) observed in humans after administration of 
conventional doses (Cmax; closed symbols and plain lines). The ordinate shows the change in 
the number of CFU (log scale) per mL for extracellular bacteria or per mg of cell protein for 
intracellular bacteria. The plain horizontal line corresponds to a bacteriostatic effect (no 
change from initial inoculum) and the dotted horizontal line shows the limit of detection (-4.5 
log10 CFU decrease). Values are means ± standard deviations (n = 3); when not visible, error 
bars are smaller than the symbols. 
 
Buyck et al. Antibiotic activity towards intracellular P. aeruginosa - Page 6 of 7 
 
Buyck-et-al-Intracellular-Pseudomonas-23-02-2013-SP.doc 
Last saved by Françoise Van Bambeke - 25/02/2013 09:44:59 AM 
 
Buyck et al. Antibiotic activity towards intracellular P. aeruginosa - Page 7 of 7 
 
Buyck-et-al-Intracellular-Pseudomonas-23-02-2013-SP.doc 
Last saved by Françoise Van Bambeke - 25/02/2013 09:44:59 AM 
 
